<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Samsung Biologics, Amgen and Biocon invest in US pharma sites — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Samsung Biologics, Amgen and Biocon invest in US pharma sites</h2>
    <div class="badge">2025-09-15T12:14:00+00:00</div>
    <ul>
      <li>Prior to that, it landed a $1.2 billion manufacturing contract with an Asia-based pharmaceutical company in October 2024.</li>
<li>The company said it has invested more than $40 billion in manufacturing and R&amp;D since the passage of the Tax Cuts and Jobs Act of 2017.</li>
<li>Amgen designated about $5 billion for U.S.</li>
<li>In April, Samsung Biologics inked a separate $514 million deal with an undisclosed U.S.</li>
<li>In 2020, Samsung Biologics opened a laboratory in San Francisco and continues to weigh U.S.</li>
<li>It is the second-biggest since the company’s founding in 2011, Korea JoongAng Daily reported.</li>
<li>pharma South Korea-based Samsung Biologics has struck a nearly $1.3 billion supplier deal with an undisclosed U.S.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Samsung Biologics, Amgen and Biocon invest in US pharma sites\n• Prior to that, it landed a $1.2 billion manufacturing contract with an Asia-based pharmaceutical company in October 2024.\n• The company said it has invested more than $40 billion in manufacturing and R&amp;D since the passage of the Tax Cuts and Jobs Act of 2017.\n• Amgen designated about $5 billion for U.S.\n• In April, Samsung Biologics inked a separate $514 million deal with an undisclosed U.S.\n• In 2020, Samsung Biologics opened a laboratory in San Francisco and continues to weigh U.S.\n• It is the second-biggest since the company’s founding in 2011, Korea JoongAng Daily reported.\n• pharma South Korea-based Samsung Biologics has struck a nearly $1.3 billion supplier deal with an undisclosed U.S." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/m/e5f25881-fff5-3199-870d-760af03a56cc/samsung-biologics%2C-amgen-and.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>